Celcuity Inc. and NCS Multistage Holdings Inc. in race to be NASDAQ top performer of the day
The National Association of Securities Dealers Automated Quotations (NASDAQ) Composite Index opened at 13,787.02 on 9th April 2021. Till 1 PM the highest it touched was 13,845.13 and lowest 13,748.35
Top 5 Performers Till 1 PM:
Celcuity Inc. (Change 43.26% Priced at $20.5)
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
NCS Multistage Holdings Inc. (Change 43.13% Priced at $35.2)
NCS Multistage Holdings, Inc. engages in the provision of engineered products and services that facilitate the optimization of oil and natural gas well completions and field development strategies. It offers fracturing systems, repeat precision, tracer diagnostics, and well construction. The company was founded by Robert Nipper and Marty Stromquist in 2006 and is headquartered in Houston, TX.
MEDIROM Healthcare Technologies Inc. ADR (Change 34.40% Priced at $15.5)
MEDIROM Healthcare Technologies, Inc. owns, develops, operates, manages, and supports relaxation salons through the franchising and direct ownership of such salons. It provides relaxation and bodywork services. The firm operates two synergistic lines of businesses: Relaxation Salon Segment (retail) and Digital Preventative Healthcare Segment (healthtech). The company was founded by Kouji Eguchi on July 13, 2000 and is headquartered in Tokyo, Japan.
Affimed N.V. (Change 23.00% Priced at $9.7)
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Tenax Therapeutics Inc. (Change 20.79% Priced at $2.1)
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company has a world-class scientific advisory team, including recognized global experts in pulmonary hypertension. The company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
